1. The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member States, 3 Associated Countries and 1 third Country. By concentrating transnational resources, TRANSCAN-2 will furnish a critical financial and scientific mass for tackling large-scale problems, relevant for improving translational cancer research globally. TRANSCAN-2 Objectives The principal objectives are to contribute to the building and enlarging the research network through the coordination of national and regional translational cancer research funding organisations’ activities, focusing on the integration of basic, clinical and epidemiological cancer research and facilitation of transnational cancer funding in and outside Europe, with the final aim to streamline world-wide cancer screening, early diagnosis, prognosis, treatment and care. Cancer is a worldwide health burden and a major public health challenge in Europe, responsible for 25% of all deaths, and the situation is expected to worsen with population ageing. The improvement of transnational cancer research appears a critical need for the development and validation of novel therapeutic strategies to reduce incidence and mortality of malignancies and to improve the quality of life of the cancer patients. TRANSCAN-2 http://www.transcanfp7.eu ERA-NET: Aligning national/regional translational cancer research programmes and activities

2.  Management and network coordination of all the activities.  Design and implementation of the first joint transnational call (JTC 2014) Cofounded by the EC.  Development and update strategies for TRANSCAN-2 network functioning and for identification of scientific priority topics in translational cancer research  Design and implementation of three additional joint transnational calls (JTCs).  Monitoring of research projects funded within TRANSCAN-2 JTCs, including the co- funded JTC 2014, communication and dissemination of their achieved results, as well as communication and dissemination of the TRANSCAN-2 consortium activities.  Monitoring and assessment of the cooperation between funding agencies in TRANSCAN-2 consortium in order to improve procedures and to identify best practices in the new ERA-NET Cofound instrument. TRANSCAN-2 Work Plan

3. TRANSCAN-2 Strategic impact TRANSCAN-2 will strongly contribute to the building and enlarging of a more effective European Research Area by facilitating and coordinating regional, national and joint European cancer research funding programmes among European Member States, Associated Countries and third Countries. TRANSCAN-2 brings together an exceptional consortium of major European and non European funding organisations and agencies with the common aim and commitment to accelerate the translation of scientific discoveries into clinical applications and to increase the quality of cancer research. TRANSCAN-2 will coordinate and focus, together with the European Commission endorsement, the available resources of its partners on strategic areas of mutual importance in order to support the translational cancer research in Europe, both on national and European level. TRANSCAN-2 will create added value for the construction of the European Research Area by developing strategic synergies also on a higher organisational level, namely by establishing or further developing strong links with relevant international or European-funded collaborations and consortia. TRANSCAN-2 will contribute to the structuring of human resources in translational cancer research, by supporting capacity building and training activities of multi-disciplinary research teams in the context of the planned joint transnational calls. This will promise cross-border synergies in the organization of human resources, ensuring better exploitation of intellectual potential in pre-clinical and clinical translational cancer research. TRANSCAN-2 will have a strong positive impact on the setting up of a sustainable European network for the funding of translational cancer research, by promoting integration and efficient use of resources concerning research policies. The joint transnational calls launched by TRANSCAN-2 will promote not only scientific excellence, through competition for funds and peer review evaluation, but also the achievement of the critical mass that is an absolute requirement for conducting long-term research on new preventive, diagnostic and therapeutic tools and interventions, with a comprehensive approach and a subject/patient-oriented attitude. The funding of multinational translational cancer research projects will also enforce the coordination of academic clinical trials, i.e. independent clinical research. At the same time, it will release the potential of scientific discoveries and interventions to be transferred into innovative products and services capable of boosting competitiveness. Thus, TRANSCAN-2 will have a positive impact in increasing the attractiveness of Europe for the biomedical and biotechnology industry focused on the development of anti-cancer interventions.

4. TRANSCAN-2 Partners NameShort nameCountry Austrian Science FundFWFAustria Research Foundation - FlandersFWOBelgium - Flanders Fund for Scientific ResearchFNRSBelgium – French Speacking community Estonian Research CouncilETAgEstonia National Cancer InstituteINCaFrance ARC French Foundation for Cancer ResearchARCFrance Federal Ministry of Education and ResearchBMBFGermay German Aerospace CentreDLRGermany General Secretariat for Research and Technology, Ministry of Education and Religious Affairs GSRTGreece National Institute of OncologyOOIHungary The Chief Scientist Office of the Ministry of HealthCSO-MOHIsrael Ministry of HealthMoHItaly Ministry of Education, Universities and ResearchMIURItaly National Institute of HealthISSItaly Alliance Against CancerACCItaly Latvian Academy of SciencesLASLatvia Dutch Cancer SocietyDCSNetherlands The Netherlands Organisation for Health Research and Development ZonMwNetherlands The Research Council of NorwayRCNNorway Norwegian Cancer SocietyNCSNorway National Centre for Research and DevelopmentNCBRPoland Foundation for Science and TechnologyFCTPortugal Slovak Academy of SciencesSASSlovakia Ministry of Education, Science and SportMIZSSlovenia National Institute of Health Carlos IIIISCIIISpain The Foundation for the support of the Applied Scientific Research and Technology in Asturias FICYTSpain Ministry Of Science And TechnologyMoSTTaiwan The Scientific and Technological Research Council of Turkey TUBITAKTurkey